Stockholm-based Sprint Bioscience, which conducts early preclinical drug development primarily targeting cancer, announced on Thursday morning that it had raised 20.7 MSEK in a share issue directed at a group of existing and external investors. BioStock has contacted the company’s CEO Erik Kinnman to find out more about what it means for the company.
Read the full article at biostock.se:
This is a press release from BioStock – Connecting Innovation & Capital.https://www.biostock.se
